Taken together, these data indicate that increased p-ERBB4, either independently of or together with increased p-EGFR, is associated with significantly shorter patient survival, suggesting that increased p-ERBB4 may be a prognostic marker for GBM. Here, ERBB4 is linked to glioblastoma.